BET Inhibitors Cancer Therapy Breakthrough

A new study by the Max Planck Institute of Immunobiology and Epigenetics, led by Asifa Akhtar and with Umut Erdoğdu as first author, has provided a crucial explanation for the disappointing results of BET inhibitors in cancer trials. The research reveals that two key BET proteins, BRD2 and BRD4, perform distinct roles in gene activation, rather than acting similarly as previously assumed. BRD2 initiates gene transcription by organizing molecular machinery and responding to specific chemical tags, while BRD4 drives the later stage of active transcription. Current BET inhibitors block both proteins simultaneously, leading to unpredictable and context-dependent effects. The findings suggest that distinguishing between the roles of BRD2 and BRD4 could lead to more precise and effective cancer treatments, marking a significant step forward in precision oncology. The study was published in Nature Genetics.